Frequency of S-G2M Cells in PBPC Enriched by Immunoaffinity Removal of Lineage-Positive Cells and Still Viable After Exposure to Both Mafosfamide and Taxol or to 5-FU, SCF, and IL-3
Experiment No. . | Frequency of S-G2M Cells (% of all cells) . | |
---|---|---|
. | Drug Exposure After PBPC Enrichment . | 5-FU, SCF, and IL-3 . |
. | Mafosfamide and Taxol . | . |
1 | 1.7 | 0 |
2 | 1.3 | 0 |
3 | 1.2 | 0.1 |
4 | 0.7 | 0 |
5 | 2.1 | 0 |
6 | 1.1 | 0 |
7 | 1.4 | 0.1 |
Experiment No. . | Frequency of S-G2M Cells (% of all cells) . | |
---|---|---|
. | Drug Exposure After PBPC Enrichment . | 5-FU, SCF, and IL-3 . |
. | Mafosfamide and Taxol . | . |
1 | 1.7 | 0 |
2 | 1.3 | 0 |
3 | 1.2 | 0.1 |
4 | 0.7 | 0 |
5 | 2.1 | 0 |
6 | 1.1 | 0 |
7 | 1.4 | 0.1 |
Abbreviations: PBPC, peripheral blood progenitor cell; FU, fluorouracil; SCF, stem cell factor; IL, interleukin.